NEW YORK—Porter Novelli has acquired Atkins + Associates, a leading life sciences agency based in San Diego and established a dedicated life sciences business unit, Porter Novelli Life Sciences, which incorporates the life sciences team of Porter Novelli subsidiary, FischerHealth, and will provide support to biotech and life sciences companies of all sizes.
Operating under the Porter Novelli Life Sciences name, Atkins + Associates will retain all of its management team and staff, as well as its focus on the life sciences sector. Porter Novelli Life Sciences will have offices in San Diego and New York.
“We believe much of the life sciences industry has been underserved in terms of quality and breadth of service available,” says Helen Ostrowski, CEO of Porter Novelli. “The combined resources and expertise of Atkins + Associates, FischerHealth’s life sciences team and Porter Novelli create what we believe is the most compelling agency opportunity in the life sciences market.
“Merging well-established life sciences resumes with international health care resources gives Porter Novelli Life Sciences the ability to tackle an expansive, diverse range of client assignments, from biotech start-ups to major commercial ventures.”
Porter Novelli Life Sciences will be led by three biotech veterans: Carin Canale, president; Amy Martini, executive vice president; and Miriam Weber, executive vice president. Canale was previously managing director at Atkins + Associates and partnered with Susan Atkins to build one of the most respected life science brands in the industry. Martini and Weber have been co-leads of FischerHealth’s life sciences practice, which they successfully developed after FischerHealth was acquired by Porter Novelli.
Porter Novelli Life Sciences will report to Greg Baird, a Porter Novelli partner and leader of its healthcare industry group.
“Our clients—as well as our client roster—are growing, and we are now able to offer an even broader array of national and international services to help them succeed in the very competitive arena of life sciences,” says Atkins.